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Summary We have established a reliable method to induce invasive and non-invasive carcinomas in the
heterotopically transplanted urinary bladder of rats by repeated injection of N-methyl-N-nitrosourea (MNU).
and examined the alterations of the ras oncogenes and ras oncogene product (p21) in the induced tumours.
The incidence of muscle-invasive carcinomas was proportional to the total dose of MNU. When 5, 6 or 12
doses of MNU were used, muscle invasive carcinomas developed in 22, 58 or 45% of animals, respectively,
after a mean observation period, respectively, of 54 ± 9, 45 ± 13 and 38 ± 3 weeks. Whereas activated H-ras
gene was detected in only one non-invasive carcinoma by DNA transfection assay, seven of 18 non-invasive
and invasive carcinomas showed activated ras p21 when examined by immunoblot analysis. Amplification or
rearrangement of myc or epidermal growth factor (EGF) receptor gene was not observed. The results indicate
that alterations of ras gene may be involved in the development of rat bladder carcinomas but not of
invasiveness.
Human bladder cancer can be divided into two types; a
majority of them are low-grade papillary carcinomas only
superficially invasive, whereas as many as 20% of tumours
are deeply invasive potentially lethal carcinomas (Kaye &
Lange, 1982; Brawn, 1982). When human bladder cancers
were tested for transforming activity using NIH3T3 cells,
activated H-ras was demonstrated in approximately 10% of
randomly selected tumours (Fujita et al., 1984; Fujita et al.,
1985), and there was no correlation between H-ras activation
and the degree of invasiveness of tumours. As in human
carcinomas, the rate of ras oncogene activation is infrequent
in carcinogen-induced rat bladder carcinomas (Fujita et al.,
1988; Debiec-Rychter et al., 1989). Thus the significance of
ras gene alterations in the development of urinary bladder
cancer in general and of deeply invasive carcinoma in partic-
ular remains unclear. Though several models are available
for the induction of rat urinary bladder cancer, the frequency
of deeply invasive carcinoma is low and requires an extended
period of observation (Kunze, 1979). In this study, the
heterotopically transplanted rat urinary bladder system
(HTB) was used for the induction of urinary bladder car-
cinomas. It was developed in our laboratory to study the role
of urine on bladder carcinogenesis (Oyasu et al., 1976; Oyasu
et al., 1978). The system is also suited to test the effect of
topically applied carcinogen because urinary tract infection
and subsequent calculus formation, the two common compli-
cations which frequently occur after repeated intravesical
administration of test substances can be avoided with the
HTB system. Though useful for testing direct effects of test
compound on the bladder mucosa, disadvantages include
meticulous care of the HTB to avoid infection and the fact
that periodic spontaneous emptying (micturition) cannot be
expected to occur. We had two objectives, to establish a
reliable method to induce non-invasive and deeply invasive
carcinomas after MNU administration and to examine the
alterations of the ras genes and ras gene product (p21) in
these tumours.
Materials and methods
Induction ofcarcinomas in heterotopically transplanted bladder
(HTB)
The HTB system was established in male Fischer 344 rats by
the published method (Oyasu et al., 1976; Oyasu et al., 1978;
Babaya et al., 1982). In brief, a bladder taken aseptically
from donor rat was connected to a reservoir (Babaya et al.,
1982) through an intervening silastic tubing. The bladder-
reservoir unit was then transplanted into a syngeneic
recipient in such a way that the bladder portion was placed
within the gluteal muscle and the reservoir portion was in the
dorsal subcutaneous tissue. The skin incision was closed with
metal clips. Four weeks after transplantation of urinary blad-
der, recipients in the first two groups received instillation into
HTBs 0.5 mg of N-methyl-N-nitrosourea (MNU) (ICN Phar-
maceutical, NJ) dissolved in 0.5 ml of physiologic saline once
a week for 2 weeks (Figure 1). Since the HTB system is a
blind pouch, the injected material will not be lost by micturi-
tion, but will be absorbed through the mucosa. Therefore
MNU will be taken up by the urothelial cells exerting
genotoxic effects. The compound is alkali labile, and car-
cinogenic effects on other organs are not expected to take
place. After 20 weeks, group 2 rats received 0.5 mg of MNU
for three consecutive weeks. Group 3 and 4 rats received
0.5 mg of MNU once a week for 6 weeks. After 16 weeks,
group 4 rats received additional 6-weekly doses of 0.5 mg
MNU. Ten weeks after bladder transplantation, all HTBs
received 0.5 ml of normal sterilised rat urine once a week
until termination of the experiment. The injected urine is
expected to be completely absorbed in 48 h (Hirao et al.,
1980). Rats were allowed to live until a majority of the HTBs
in the group became markedly distended and the bladder
aspirate haemorrhagic. These changes were indicative of
tumour development (Oyasu et al., 1976; Oyasu et al., 1978).
When large, tumours were divided into four parts, one part
used for transplantation in nude mice, a second for explant
culture, a third for storage at - 80°C for DNA extraction
and the fourth for light microscopic examination. Small
tumours were submitted for histologic examination only.
Tumours were classified by grade, stage, and histologic type
(Oyasu et al., 1987) (see also Table I for definition).
Explant culture
Tumour tissue was minced into 1 mm3 pieces and placed in
Petri dishes coated with rat tail collagen gel and with a small
amount of Ham's F-12 (GIBCO, Grand Island, NY) supple-
mented with 10% foetal bovine serum, penicillin (100 u ml-')
and streptomycin (1001g ml-'), and incubated in a humidi-
fied atmosphere of 5% CO2 and 95% air. Outgrowths of
carcinoma cells were placed on new collagen gel-coated
dishes to establish secondary growth. This procedure was
repeated twice to remove fibroblast contamination. When a
monolayer of carcinoma cells was obtained, the culture was
passaged to new dishes. NIH3T3 cells were grown in Dulbecco's
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Figure 1 Experimental design for induction of bladder car-
cinomas by MNU. HTBs heterotopically transplanted 4 weeks
earlier (V) received 0.5mg of MNU (+) once a week for 2
(groups 1 and 2) or 6 (groups 3 and 4) weeks. After 15 weeks,
group 2 and 4 rats received 0.5 mg of MNU once a week for an
additional 3 and 6 weeks, respectively. All rats received into
HTBs 0.5 ml ofnormal rat urine once a week until termination of
the experiment.
modified essential medium supplemented with 10% calf
serum (Flow Laboratories, McLean, VA).
DNA transfection assay
DNA extracted (Andersson et al., 1979) from tumour cells
was transfected to NIH3T3 cells by the published method
(Andersson et al., 1979). Control DNA was obtained from
five normal rat urinary bladders.
Southern blot hybridisation
DNA (10-20pg) isolated from tumours on cell lines was
digested with BamHI, HindIlI or EcoRI under the conditions
recommended by the manufacturer (Boehringer Manheim,
Indianapolis, IN). The resulting DNA fragments were
separated by gel electrophoresis and immobilised on a nitro-
cellulose membrane. Southern blot hybridisation was per-
formed under stringent conditions (50% formamide, 5 x SSC
and 42°C) with 32P-labelled probes (3.0 x 106 c.p.m.) obtained
by nick translation (Rigby et al., 1977). The probes used were
v-H-ras, v-K-ras, v-myc (Oncor, Gaitherburg, MD), p5lC-
and pHER A64-1 (ATCC, Rockville, MD).
Immunoblot
Protein was extracted from tumour cells (Meyers et al., 1989)
and ras p21 was concentrated by immunoprecipitation
(Finkel et al., 1984) with rat monoclonal antibody Y13-259
(Oncogene Science, Inc., Manhasset, NY), which recognises
the products of normal or activated H-ras, K-ras and c-N-ras
(Furth et al., 1982). Immunoprecipitates were collected by
centrifugation, washed, boiled in sample buffer, and resolved
by SDS-polyacrylamide electrophoresis (Laemmli, 1970). Fol-
lowing transfer to nitrocellulose membranes (Towbin et al.,
1979) and subsequent blocking with bovine serum albumin in
PBS, membranes were incubated with the following anti-
bodies; Y13-259, mouse monoclonal antibodies recognising
the twelfth position substitutions with valine (DWP), arginine
(R256), glutamic acid (E184) (DuPont, Boston, MA) or class-
matched myeloma control proteins MOPC-141 (IgG2b) (Lit-
ton Bionetics, Charleston, SC) and MOPC-21 ((IgGl) (Cap-
pel, West Chester, PA). As positive controls, T24 human
bladder cancer cells (glycine to valine at codon 12), S2-721
cells (NIH3T3 cells transformed by a rat H-ras oncogene
activated by a GGA ->GAA mutation in codon 12, encoding
glutamic acid) and 118-413 cells (NIH3T3 cells transformed
by a human K-ras oncogene activated by a GGT -*CGT
mutation in codon 12, encoding arginin) were used. Memb-
ranes were then incubated with either rabbit anti-rat
horseradish peroxidase or biotinylated anti-mouse
horseradish peroxidase, and then incubated with diaminoben-
zidine substrate to complete the reaction.
Results
Incidence ofcarcinomas in HTBs
The treatment with 12 doses (group 4) yielded the highest
tumour incidence (100%) despite shorter study period (38 ± 3
Table I Incidence and histologic classification of MNU-induced urinary bladder
carcinomas in HTBs
Groups
1 2 3 4
MNU treatmenta 0.5 mg x 2 0.5 mg x 2 0.5 mg x 6 0.5 mg x 6
+0.5mgx 3 +0.5mgx 6
Experimental 42 9 54 9 45 13 38 3
period (weeks)
No. of rats, total 21 9 12 20
No. of rats with tumours 14 7 10 20
No. of tumours, total 26 20 37 47
Histologic typeb
T 17 12 26 21
T+Sqd 9 7 5 8
T+Sqd+Sq 0 9 6 17
Nuclear grade
I 22 6 17 22
II 4 12 15 22
III 0 2 5 3
Stagec
P0 26 18 30 33
P1 0 0 0 5
P2 0 1 5 4
P3 0 1 2 5
aMNU (0.5 mg) was instilled into heterotopically transplanted bladder (HTB) via its
attached reservoir once a week for two (group 1), five (group 2), six (group 3) or 12
(group 4) doses. In groups 2 and 4, the second series of MNU treatment began 15 weeks
after the completion of the first series. bT, transitional; Sqd, squamoid; Sq, squamous.
The number denotes the number ofrats with indicated type of bladder tumours. CpO, 1, 2
and 3 respectively refers to the tumours limited to the mucosa, extension to lamina
propria, tunica muscularis propria and perivesical tissue.
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weeks) (Table I). The MNU dose of more than 3 mg was
effective in inducing deeply invasive carcinomas (P2 and 3)
and their incidences in groups 3 (0.5 mg x 6) and 4
(0.5 mg x 12) were, respectively, seven of 12 and nine of 20.
The tumours observed in group 1 (0.5 mg x 2) were all small
and non-invasive. These results together with our previous
findings (Oyasu et al., 1987) indicate that deeply invasive
carcinomas can be induced with 3 mg of MNU, that the
induction period can be shortened by repeating the same
treatment schedule, and that most of the invasive carcinomas
show squamous differentiation. No metastasis to regional
lymph nodes or distant organs was observed.
Growth potential andhistologicalfeatures ofrat bladder
carcinomas transplanted into nude mice
Since tumours observed in group 1 were small, only tumours
grown in groups 2, 3 and 4 were used as transplants. There
were 21 non-invasive and eight deeply invasive (P2 and 3)
carcinomas. The growth of non-invasive (NI) carcinomas was
slow; ten of 21 transplants which had attained more than
1 cm in diameter could be serially transplanted at an interval
of 10 to 15 weeks (designated as NI-I to 10). They were
sharply demarcated cystic masses containing clear serous
fluid and one or two papillary nodules. Microscopic
examination generally confirmed transitional cell character
and papillary growth pattern. Eight invasive carcinomas
(designated as I-1 to 8) grew rapidly without exception and
could be passaged at an interval of 4 to 11 weeks. Despite
the sharp circumscription they were well differentiated
squamous carcinomas invasive to adipose and skeletal muscle
tissues. Transplants in general maintained their original
morphologic and grade. Focal glandular differentiation
(adenocarcinoma) occurred in two tumours.
23.1 -
9.4 -
6.6 -
4.4
-
a b c
2.3 -
2.0 -
Figure 2 Detection of H-ras sequences in NIH3T3 cells trans-
formed by genomic DNA from MNU-induced rat bladder car-
cinoma. Hybridisation was carried out with a v-H-ras probe.
Lane a, NIH3T3 cells, lanes b and c, NIH3T3 transformants
derived from non-invasive carcinomas (NI-10 and NI-13, respec-
tively). Molecular weight markers are shown on the left margin.
Two low-grade tumours adapted to grow in vitro, NI-lI
and NI-12 (D-44), were not tumorigenic, whereas cultured
cells derived from an invasive squamous cell carcinoma (I-8)
developed into a squamous cell carcinoma.
Detection ofactivated ras oncogenes
High-molecular weight DNA was prepared from 13 primary
tumours and four nude mouse transplants. These included
seven invasive and ten non-invasive carcinomas. Seven
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Figure 3 (A) (B) Immunoblot analysis of ras p21 in normal bladder and bladder carcinomas, originally invasive (I) and
non-invasive (NI), maintained in nude mice. Normal or activated ras p21 was detected using rat monoclonal antibody Y13-259 (A)
or mouse monoclonal antibody recognising the twelfth position substitution (glutamic acid instead of glycine), E184 (B). a: Normal
bladder, b: NI-1, c: NI-2, d: NI-3, e: I-1, f: NI-4, g: NI-5, h: NI-6, i: 1-2, j: NI-7, k: NI-8, 1; I-3, m: I-4, n: 1-5, o: I-6, p: NI-9, q: 1-7,
r: 1-8, s: NI-10. HC: heavy chain of immunoglobulins; LC: light chain of immunoglobulins. Arrow indicates the normal or
activated ras p21. (C) Specificity of monoclonal antibodies used to show mutations at codon 12. ras p21 from T24 (valine at codon
12) (1), S2-721 (glutamic acid) (2) or 118-413 cells (arginine) (3) were examined using pan-reactive rat monoclonal antibody
Y13-259, a, or mouse monoclonal antibodies specific to the 12th position substitutions with valine, b, glutamic acid, c, or arginine,
d. Specificity of monoclonal antibodies was observed.
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samples developed foci. DNA derived from these foci were
subjected to Southern blot analysis using ras gene probes.
Neither K-ras nor N-ras probe detected DNA fragments
other than the endogenous mouse fragments (data not
shown), but one of the seven transformants (NI-10) con-
tained additional DNA bands that hybridised with the H-ras
probe (Figure 2, lane b). NI-10 was derived from a grade I
PO transitional cell carcinoma.
Amplification of H-ras, K-ras, myc and EGF receptor gene
was examined in ten primary tumours (five invasive and five
non-invasive) and five transplants (two invasive and three
non-invasive) and two cell lines (NI-11 and NI-12). Of these
samples, nine primary tumours and three transplants were
also used in DNA transfection assay. No amplification was
demonstrated in any sample including NI-10, which con-
tained activated H-ras gene.
Detection ofactivated ras p21 by immunoblot
All of the 18 tumour samples tested demonstrated p21 at
various densities (Figure 3). Seven of 18 carcinomas con-
tained activated ras p21 reactive with monoclonal antibody
El84 which specifically recognises the mutation from glycine
to glutamic acid at codon 12. The protein extract of NI-10
which was shown to contain activated H-ras gene by
Southern blot analysis also expressed activated ras p21. No
reactivity was demonstrated with monoclonal antibodies
DWP and R256 or negative controls MOPC-21 and 141
(data not shown).
Discussion
In the present study, we not only confirmed the previous
observation that the frequency of deeply invasive carcinomas
was proportional to MNU dose, but that the highest dose
schedule (0.5 mg x 12) was able to shorten the induction
period considerably. The tumour implants in nude mice
remained relatively stable in their phenotypic expression after
repeated passages.
One mechanism of activation of ras genes is induction of
mutation at positions 12, 13 or 61 (Tabin et al., 1982; Reddy
et al., 1982; Bos et al., 1985; Yuasa et al., 1983). In MNU-
induced rat mammary carcinomas, the H-ras-1 became activ-
ated by single amino acid substitution at the twelfth codon,
encoding glutamic acid instead of glycirie (Sukumar et al.,
1983). To clarify the effect of MNU on the ras p21 in
MNU-induced rat bladder carcinomas, we examined the
reactivity of ras p21 with antibodies which were raised
against synthetic peptides showing substitution at codon 12
of ras p21 from glycine to valine, glutamic acid, or arginine.
Specificity of these monoclonal antibodies has been ade-
quately demonstrated (Carney et al., 1986; Pullano et al.,
1989; Azuma et al., 1990). Immunoblot analysis demon-
strated that seven of 18 carcinomas tested contained
activated ras p21 with substitution with glutamic acid. Of the
nine tumours which were subjected also to DNA transfection
assay, three showed twelfth codon mutation and yet in only
one of these (NI-10) ras gene activation was demonstrable by
Southern blot hybridisation perhaps due to low sensitivity of
the assay. It has been observed that although human H-ras-1
genes mutated at codon 12, encoding glutamic acid in place
of glycine, generated transformants by transfection assay, the
cells displayed a less striking change in morphology as com-
pared to those generated by mutated ras genes which en-
coded valine (Seeburg et al., 1984). Since rare 'spontaneous'
carcinoma occurred in urine-treated HTB without carcinogen
treatment (Ozono et al., 1983) there is a possibility that ras
mutation seen in some tumours is unrelated to MNU treat-
ment.
In conclusion, our data indicate that approximately one-
half of non-invasive and invasive carcinomas induced by
MNU contain activated ras oncogenes or oncogene product
p21, but that their expression cannot be correlated to the
aggressiveness of tumours. Our data are consistent with the
previous observation that H-ras oncogenes are activated by
MNU during the initiation of rat mammary carcinogenesis
(Sukumar et al., 1983).
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